BIOMUNEX Pharmaceuticals logo

BIOMUNEX Pharmaceuticals

Biomunex Pharmaceuticals is a biopharmaceutical company focused on providing cancer therapeutics through the discovery and development of innovative bispecific antibodies.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.biomunex.com
Disease Focus
STOCK CODENon Listed
Address
14 avenue dEylau75116
Paris
France
Email
Contact Number

Biomunex Pharmaceuticals is a biopharmaceutical company focused on providing cancer therapeutics through the discovery and development of innovative bispecific antibodies.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/biomunex-pharmaceuticals” connections=”true” suffix=””]

Biomunex bispecific antibodies are tetravalent, and thus maintain the symmetry and bivalency of a classical mAb for each target, exhibiting high affinity to both targets due to avidity. Depending on the requirements of a specific application, the BIOMUNEX bispecific antibody can be produced with or without the Fc domain.

Biomunex has raised close to ‹1Mn in seed funding from business angels and grants from the French Research Ministry and the public investment bank Bpifrance.